Gedeon Richter, Astron to partner on generics; Swiss doctors urged to stop using Rotarix;

 @FiercePharma: Post-reform, pharma will market to payers. Report | Follow @FiercePharma

> Gedeon Richter and India's Astron Research agreed to jointly develop several generic products, with costs jointly funded and the end products independently marketed. Release

> Switzerland has urged doctors to temporarily stop using GlaxoSmithKline's Rotarix vaccine, regulators said on Tuesday, making it the latest country to caution against the product's use. Report

> Pfizer spent $5.6 million lobbying federal leaders and agencies in the fourth quarter on multiple aspects of the healthcare overhaul, government spending on medication and other issues, according to a quarterly disclosure. Report

> Virginia wants to join a federal lawsuit claiming that health care giant Johnson & Johnson paid tens of millions of dollars in kickbacks so nursing homes would put patients on its schizophrenia drug. Report

> Some Jordanian pharmaceutical companies fear that operations of the Israeli company Teva Pharmaceutical Industries Ltd. may affect them if it chooses to cooperate with a local company. Article

> Medicare will pay for the use of facial filling treatments in certain HIV patients with sunken cheeks and other similar problems who are also depressed. Report

> A subsidiary of Abbott Laboratories has started its cash tender offer for Facet Biotech. Report

> Sanofi-Aventis and Bristol-Myers Squibb say their Duoplavin-Duocover combination tablet has been approved in the European Union. Report

> GEA Pharma Systems has opened a factory in India, aiming to reduce the cost of solid dose and liquid pharmaceutical processing equipment by around 40 percent compared with Europe. Report

> Montgomery Township officials are still keeping a close eye on Teva Pharmaceuticals' proposed warehouse development in neighboring Warrington Township. Item

Biotech News

 @FierceBiotech: Merck KGaA puts Stimuvax trial on hold after encephalitis strikes. Report | Follow @FierceBiotech

 @JohnCFierce: Carl Icahn is having a heck of a week in biotech. Genzyme black eye, talking up Biogen sale. And it's only Wednesday | Follow @JohnCFierce

> Zalbin data underscores new option for hepatitis C patients. Article

> Switzerland's Lonza is reportedly in talks to acquire control of Aptuit Laurus, a large drug R&D/manufacturing operation with 600 employees in India. Story

> Struggling Poniard lays off more workers as it ponders options. Report

> Like a lot of biotech companies, Tempe, AZ-based Capstone (CAPS) Therapeutics has high hopes for its mid-stage program. If its Phase II trial of AZX100 for scar reduction produces promising proof-of-concept data, its executive chairman says the drug has blockbuster market potential. Item

> Vernalis shares dive after pain program flunks Phase IIb. Story

Medical Device News

> Device industry mixed on healthcare reform. Story

> Panel questions data backing ReGen's Menaflex device. Article

> CryoLife fires back in HemoStase dispute. Report

And Finally... Live right and Americans could all live an extra 4 to 5 years. Report